Replies to post #187096 on Biotech Values

[oldberkeley]

I don’t think Hamburg’s resignation affects biotech investors to a material degree.

Only if we wind up with someone worse, which could happen since she was excellent.

Folks on quite a few iHub boards—AMRN comes to mind—have demonized Dr. Hamburg and the FDA in general instead of taking a hard look at their actual investment, the company and the drug.

It’s hard not to throw that stone when decisions don’t go your way and you lose money (I’ve been guilty of that myself) but in general I think she’s done a good job.

[MiamiGent]

Commissioners come with personal agendas- things they'd like to accomplish for their legacy. For instance, Hamburg's was, in part, to get worthy drugs through the gate. Gleaning that helped long range biotech investors with probability and timing considerations.
Commissioners may feel certain areas are lagging and want to give impetus to those. The shrewd biotech investor wants to know what those impetuses will be.
Is a commissioner going to be susceptible to political pressures, like the last spat of diet drugs, a pet issue of Michelle Obama's and certain legislators.
Key now is, what's on the new Commissioner's agenda.

MG